Elanco Animal Health Incorporated

ELAN Healthcare Drug Manufacturers Specialty & Generic

Elanco Animal Health Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 6.22% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 450.0%, free cash flow grew 35.6% and total debt fell 6.91%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.

23.55 0.01 +0.04%
Market cap
$11.8B
P/E
0.0×
Fwd P/E
278×
Dividend yield
—
F-score
5/9
Altman Z
1.28
Beneish M
−2.68
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

287.71 0.00 0.00 0.00
P/S ratio
2.18 2.38 2.43 2.45
P/FCF ratio
28.92 42.88 40.65 34.43
P/Operating CF
45.69 104.01 916.15 44.38
P/B ratio
1.48 1.72 1.83 1.87
EV/Sales
2.95 3.12 3.16 3.12
EV/EBITDA
15.56 21.16 20.71 20.26
EV/FCF
39.09 56.13 52.81 43.92
Current Ratio
2.40 2.17 2.16 2.05
Net Debt/EBITDA
19.77 (385.78) 10.96 12.10
Debt/Equity
0.60 0.61 0.61 0.59
Earnings Yield
0.35% (2.08%) (2.09%) (1.67%)
Free Cash Flow Yield
3.46% 2.33% 2.46% 2.90%
Free Cash Flow per Share
0.26 0.09 (0.08) 0.49
Book value per Share
13.58 13.19 13.06 13.19
Free Cash Flow
127.00 46.00 (38.00) 244.00
EV/EBIT
67.96 980.37 276.30 193.59
Other line items

Show all line items

Columns are period end dates